FilingReader Intelligence
Sun Pharma settles LEQSELVI litigation with Incyte
July 14, 2025 at 11:09 AM UTC•By FilingReader AI
Sun Pharmaceutical Industries announced a settlement and license agreement with Incyte Corporation regarding litigation over LEQSELVI (deuruxolitinib).
Sun Pharma will pay an upfront amount and ongoing royalties for a limited, non-exclusive license to certain U.S. patents for non-hematology-oncology indications. The pending litigation will be dismissed.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:SUNPHARMA•Bombay Stock Exchange
News Alerts
Get instant email alerts when Sun Pharmaceutical Industries publishes news
Free account required • Unsubscribe anytime